Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Baxter

Showing results (231-240 of 242) with videos related to

Pageof 25
Sort By:
Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.
Nature Biotechnology|July 17, 2018
Comprehensive multi-center assessment of small RNA-seq methods for quantitative miRNA profilingMaria D Giraldez, Ryan M Spengler, Alton Etheridge, et al.
Nature Biotechnology|September 7, 2018
Erratum: Comprehensive multi-center assessment of small RNA-seq methods for quantitative miRNA profilingMaria D Giraldez, Ryan M Spengler, Alton Etheridge, et al.
The Lancet. Infectious Diseases|January 22, 2021
Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey resultsJenny M MacLennan, Charlene M C Rodrigues, Holly B Bratcher, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 15, 2022
Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programmeJeremy P Carr, Jenny M MacLennan, Emma Plested, et al.
Nature Communications|May 7, 2025
Genomic landscape of diffuse glioma revealed by whole genome sequencingBen Kinnersley, Josephine Jung, Alex J Cornish, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
Pageof 25

Showing results (231-240 of 242) with videos related to

Sort By:
Pageof 25
Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.
Nature Biotechnology|July 17, 2018
Comprehensive multi-center assessment of small RNA-seq methods for quantitative miRNA profilingMaria D Giraldez, Ryan M Spengler, Alton Etheridge, et al.
Nature Biotechnology|September 7, 2018
Erratum: Comprehensive multi-center assessment of small RNA-seq methods for quantitative miRNA profilingMaria D Giraldez, Ryan M Spengler, Alton Etheridge, et al.
The Lancet. Infectious Diseases|January 22, 2021
Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey resultsJenny M MacLennan, Charlene M C Rodrigues, Holly B Bratcher, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 15, 2022
Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programmeJeremy P Carr, Jenny M MacLennan, Emma Plested, et al.
Nature Communications|May 7, 2025
Genomic landscape of diffuse glioma revealed by whole genome sequencingBen Kinnersley, Josephine Jung, Alex J Cornish, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
Pageof 25